AI @ Merck & Co.
Summary
- Merck has progressively integrated generative AI and machine learning into its drug discovery and development processes since late 2023, with expanded partnerships (e.g., Vector Institute, Variational AI) and strategic collaborations (e.g., Boston Consulting Group, McKinsey).
- By mid-2025, Merck developed advanced internal generative AI platforms, including foundation models like TEDDY with 400M parameters, enhancing disease inference accuracy and accelerating target identification from years to weeks, leading to tangible product developments such as the KRAS G12C inhibitor MK-1084 with positive Phase I results.
- In early 2026, Merck extended its AI applications to support precision medicine through collaboration with Mayo Clinic, deploying AI for improved clinical trial workflows and decision-making, reflecting a sustained, mature adoption of AI technologies across research, manufacturing, and clinical activities.
VIBE METER
5 AI Use Cases at Merck & Co.
Precision Medicine2026
Clinical Authoring2025
Target Identification2025
Disease Insight2024
Timeline
2026 Q2: no updates
2026 Q1
Merck and Mayo Clinic launched research collaboration applying AI and advanced analytics to strengthen early drug development decisions and precision medicine capabilities; Merck communicated broader AI impact initiatives to accelerate patient access to medicines.
2025 Q4
Merck embraced agentic and generative AI tools to strategically augment human decision-making and place experts 'in the right room,' addressing concerns about AI autonomy through effective human-AI collaboration.
2025 Q3
Merck signed $349 million biobucks deal to expand AI-driven small molecule drug discovery with Variational AI focused on challenging targets; also accelerated clinical report drafting timelines from weeks to days using AI.
2025 Q2
Merck expanded internal generative AI solutions reducing clinical study documentation time by over 80%; developed foundation model TEDDY (400M parameters) to improve disease inference by 10%; AI designed KRAS G12C inhibitor MK-1084 showed positive Phase I results; leadership emphasized tailored AI solutions embedded in business functions.
2025 Q1
Merck utilized AI to accelerate drug manufacturing and discovery; AI augmented human researchers in target identification and molecule optimization, with emphasis that humans remain in the loop to validate AI outputs.
2024 Q4
Merck published an AI 360° perspective demonstrating AI usage to drive efficiency and innovation across Life Science, Healthcare, and Electronics; a scientist discussed AI enhancing insights into disease biology undetectable by humans.
2024 Q3
Merck emphasized AI's transformative potential across its culture and operations, highlighting ongoing efforts to harness AI for innovation and productivity improvements across life sciences and healthcare.
2024 Q2
Merck KGaA engaged AI-focused biotech Biolojic Design for oncology and immunology drug discovery; Merck (MSD) announced strategic generative AI collaboration with Boston Consulting Group to enhance innovation and efficiency.
2024 Q1
Merck partnered with Vector Institute to access a broad AI research ecosystem; also began collaboration with Variational AI to evaluate generative AI platforms for novel small molecule design, positioning itself as an early adopter of generative AI drug discovery tools.
2023 Q4
Merck launched its first AI solution integrating generative AI, machine learning, and computer-aided drug design to accelerate drug discovery and synthesis, leveraging over two decades of data.